| Authors: |
Bellmunt J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: joaquim_bellmunt@dfci.harvard.edu., Powles T; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, St Bartholomew's Hospital, London, UK., Park SH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Voog E; Centre Jean Bernard Clinique Victor Hugo, Le Mans, France., Valderrama BP; Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain., Gurney H; Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia., Ullén A; Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, Solna, Sweden., Loriot Y; Gustave Roussy, INSERMU981, Université Paris-Saclay, Villejuif, France., Sridhar SS; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Tsuchiya N; Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan., Sternberg CN; Englander Institute for Precision Medicine, Meyer Cancer Center, New York, NY, USA., Aragon-Ching JB; Inova Schar Cancer Institute, Fairfax, VA, USA., Petrylak DP; Yale Cancer Center, New Haven, CT, USA., Climent Duran MA; Instituto Valenciano de Oncología, Valencia, Spain., Tyroller K; EMD Serono Research & Development Institute, Inc. (an affiliate of Merck KGaA), Billerica, MA, USA., Hoffman J; EMD Serono Research & Development Institute, Inc. (an affiliate of Merck KGaA), Billerica, MA, USA., Jacob N; Merck Healthcare KGaA, Darmstadt, Germany., Grivas P; Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA., Gupta S; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. |
